| Axitinib Extends Progression-Free Survival in Kidney Cancer Trial - Internal Medicine News Digital Network |
|
|
Internal Medicine News Digital Network CHICAGO – The investigational drug axitinib prolonged median progression-free survival by 2 months, compared with sorafenib, in a randomized, phase III trial that was conducted in patients with metastatic renal cell carcinoma resistant to initial |